NCT03508011View on ClinicalTrials.gov

A Study of IMP4297 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

August 23, 2017

Primary Completion Date

December 16, 2020

Study Completion Date

December 16, 2020

Conditions
Advanced Solid TumoursBreast CancerOvarian CancerProstate Cancer
Interventions
DRUG

IMP4297

The dose levels will be escalated following a modified 3+3 dose escalation scheme.

Trial Locations (2)

100021

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

200032

Fudan University Shanghai Cancer Center, Shanghai

Sponsors
All Listed Sponsors
lead

Impact Therapeutics, Inc.

INDUSTRY